Recombinant Human Fms-Related Tyrosine Kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)

• Cat.No.: FLT1-1221H
• Product Overview: Recombinant humansoluble FLT1 is the naturally occurring form and was cloned from total RNA ofhuman umbilical vein endothelial cells.

Specification

• Cat. No.: FLT1-1221H
• Description: The recombinant mature soluble FLT1 is aglycosylated monomeric protein consisting of the first 6 extracellulardomains (Met1-His688) containing the unique 31 amino acid residues at theC-terminus.
• Source: Insect cells
• Species: Human
• Form: Lyophilizedwithout additives.
• Molecular Weight: 96 kDa
• Purity: > 90% asdetermined by SDS-PAGE and visualized by silver stain
• Endotoxin Level: < 0.1 ng/µg of FLT1
• Biological Activity: Determined by itsability to abolish the binding of iodinated FLT1 to solid surfaces or cellsurface receptors. The ED50 for this effect is typically 10 ng/ml. The usablerange is 5-50 ng/ml.
• Reconstitution: Centrifugevial prior to opening. Soluble in water and most aqueous buffers. Add PBS tothe vial to fully solubilize the protein to a concentration not lower than100 ng/ml.
• Storage: Lyophilized proteinis stable for 6 months at -20°C to -80°C. Store reconstituted protein inworking aliquots at -20°C. Avoid repeated freeze-thaw cycles.

Gene Information

• Gene Name: FLT1 fms-related tyrosine kinase 1(vascular endothelial growth factor/vascular permeability factor receptor) [ Homosapiens ]
• Official Symbol: FLT1
• Synonyms: FLT1; fms-related tyrosinekinase 1 (vascular endothelial growth factor/vascular permeability factorreceptor); FLT; VEGFR1; FRT; vascular endothelial growth factor receptor 1;EC 2.7.10.1; VEGFR-1; Vascular permeability factor receptor; Flt-1;Tyrosine-protein kinase receptor FLT; Tyrosine-protein kinase FRT; Fms-liketyrosine kinase 1
• Gene ID: 2321
• mRNA Refseq: NM_001159920
• Protein Refseq: NP_001153392
• MIM: 165070
• UniProt ID: P17948
• Chromosome Location: 13q12
• Pathway: Cytokine-cytokinereceptor interaction; Endocytosis; Focal Adhesion; Glypican 1 network;HIF-2-alpha transcription factor network; Id Signaling Pathway; Neurophilininteractions with VEGF and VEGFR; Rheumatoid arthritis; S1P3 pathway; SignalTransduction; Signaling by VEGF; Signaling events mediated by VEGFR1 andVEGFR2; VEGF binds to VEGFR leading to receptor dimerization; VEGFligand-receptor interactions; VEGFR1 specific signals
• Function: ATP binding; growth factorbinding; identical protein binding; nucleotide binding; receptor activity;transferase activity; vascular endothelial growth factor receptor activity

Reviews

07/08/2019

the FLT1 protein is an excellent choice for researchers due to its high quality, reliability, and the comprehensive technical support provided by the manufacturer.

07/17/2018

The manufacturer of FLT1 protein provides excellent technical support, ensuring that researchers receive prompt assistance and guidance when encountering any challenges or difficulties.

05/27/2016

Researchers can confidently incorporate FLT1 protein into their experiments, knowing that they have access to a reliable resource that will meet their experimental needs effectively.

Q&As

How is FLT1 linked to preeclampsia in pregnancy?

Elevated levels of soluble FLT1 have been associated with preeclampsia, a pregnancy complication. Soluble FLT1 acts as a decoy receptor, reducing the bioavailability of VEGF and contributing to vascular dysfunction.

How does FLT1 contribute to retinal diseases such as diabetic retinopathy?

FLT1 has been implicated in retinal diseases like diabetic retinopathy, where abnormal blood vessel growth can lead to vision impairment. Inhibiting FLT1 may help regulate angiogenesis in such conditions.

How is FLT1 expression regulated in the human body?

FLT1 expression is regulated by various factors, including VEGF itself, as well as hypoxia and inflammation. These factors influence the balance of angiogenic signaling.

Can FLT1 be a biomarker for certain diseases?

Yes, elevated levels of soluble FLT1 have been investigated as potential biomarkers for conditions like preeclampsia, cancer, and certain cardiovascular diseases.

Can FLT1 be targeted for anti-angiogenic therapy?

Yes, targeting FLT1 is a strategy for anti-angiogenic therapy. Inhibiting FLT1 can impede blood vessel formation, limiting the blood supply to tumors and potentially slowing their growth.